This will help prevent latanoprost/timolol from passing into the rest of the body
Repeat the procedure in the other eye, if your doctor has instructed you to do so. If the drop falls outside the eye, apply another drop.
7.Close the bottle.
If you use more Latanoprost/Timolol Stada than you should
If too many drops have entered the eye, it may causeirritation and redness.
Inform yourdoctor immediatelyif you or anyone else hasaccidentally ingestedthe drops, or if you have been using the drops more frequently than prescribed.
Have the packaging of this medication handy, so that your doctor can have more information about the medication. He/she will decide what to do.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately, or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested. It is recommended to bring the packaging and the medication leaflet to the healthcare professional.
If you forgot to take Latanoprost/Timolol Stada
If you have forgotten to use the eye drop, continue treatment by administering the next dose in the usual manner. The dose should not exceed one drop per day in the affected eye.
Do not take adouble doseto compensate for missed doses.
If you interrupt treatment with Latanoprost/Timolol Stada
Do not interrupt or stop treatment with latanoprost/timolol without first consulting your doctor.
If you do not use latanoprost/timolol regularly or if you frequently forget to administer it, thesuccess of your treatment may be at risk.
The increase in intraocular pressure (pressure inside the eye) can damage the optic nerve and worsen your vision. Blindness may occur. Normally, the increase in intraocular pressure is barely perceptible. The disorder can only be diagnosed through an examination performed by an ophthalmologist. If you have high intraocular pressure, regular eye exams, along with measurements of the internal pressure of the eye, are necessary. The pressure inside the eye should be measured at least every 3 months. Once a year, visual field measurements and optic nerve examinations should be performed.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication may cause side effects, although not everyone will experience them.
You can continue using the eye drops as usual, unless the side effects are severe. If you are concerned, consult your doctor or pharmacist. Do not stop using latanoprost/timolol without consulting your doctor.
The following describes the side effects of using an eye drop that contains the active substances latanoprost and timolol. The most important side effect is the possibility of a gradual, permanent change in the color of the eyes. It is also possible that eye drops containing latanoprost and timolol as active ingredients may cause significant changes in the functioning of your heart. If you notice changes in heart rhythm or cardiac function, you should talk to a doctor and tell them that you have been using latanoprost/timolol.
The frequency of the possible side effects described below is defined using the following convention
Very common(may affect more than 1 in 10 people):
•A gradual change in eye color by increasing the amount of brown pigment in the colored part of the eye called the iris. If your eye color is a mixture of colors (blue-brown, gray-brown, yellow-brown, or green-brown), the change may be more noticeable than if you have eyes of a single color (blue, gray, green, or brown). Any change in eye color may take years to develop. The color change may be permanent and may be more noticeable if you use latanoprost/timolol in one eye only. It does not appear to be related to any problems with the change in eye color. The change in eye color does not continue after stopping treatment with latanoprost/timolol.
Common(may affect up to 1 in 10 people):
•Irritation of the eye (sensation of burning, grittiness, itching, stinging, or feeling of a foreign body in the eye) and eye pain.
Uncommon(may affect up to 1 in 100 people):
Other side effects
The following side effects have been observed with latanoprost:
•Development of a viral eye infection caused by the herpes simplex virus (HSV)
Immune system disorders:
•Symptoms of an allergic reaction (swelling and redness of the skin and rash).
Nervous system disorders:
•Dizziness
•Changes in eyelashes and fine hair around the eye (increase in number, length, thickness, and darkness), changes in the direction of growth of eyelashes, inflammation around the eye, swelling of the colored part of the eye (iritis/uveitis), swelling in the back of the eye (macular edema), inflammation or irritation of the surface of the eye (keratitis), dry eyes, cyst filled with fluid within the colored part of the eye (iris cyst), sensitivity to light (photophobia), appearance of sunken eyes (greater depth of the eyelid fold), eye disorder affecting the cornea characterized by lesions on the corneal epithelium with a punctate pattern (punctate epithelial erosion), corneal edema (swelling and fluid retention in the cornea) and corneal erosion (damage to the anterior layer of the globe).
Heart disorders (cardiac):
•Angina, worsening of angina in patients with existing heart disease, awareness of heart rhythm (palpitations)
Respiratory disorders:
•Asthma, worsening of asthma, difficulty breathing.
Gastrointestinal disorders:
•Nausea, vomiting (uncommon).
Skin disorders:
•Darkening of the skin around the eyes
Musculoskeletal disorders:
•Joint pain, muscle pain.
General disorders:
•Chest pain.
Like other eye medications, latanoprost/timolol is absorbed into the bloodstream. The timolol portion of this combination may cause side effects similar to those that occur with intravenous and/or oral beta-blockers. The incidence of side effects after topical administration is lower than when the medications are taken, for example, orally or injected. The described side effects include reactions observed when beta-blockers are used to treat eye diseases:
In very rare cases, some patients with severe damage to the transparent front part of the eye (cornea) have developed cloudy areas in the cornea due to calcium deposits produced during treatment.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Vigilance of Medicinal Products for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep out of thesight and reach of children.
Do not use this medication after theexpiration datethat appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Please note the following conservation instructions:
Unopened bottles: Store in refrigerator at 2°C - 8°C.
After the first opening of the bottle: Do not store at a temperature above 25ºC.
Once opened, discard the bottle - with the remaining contents - after 4 weeks.
Otherwise, there is a risk of ocular infection.
Medicines should not be disposed of throughdrainsor in thetrash. Deposit the packaging and medicines you no longer need at the SIGRE collection pointat the pharmacy. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. In this way, you will help protect the environment.
Latanoprost/Timolol Stada Composition
1 ml of eye drops contains 50 micrograms of latanoprost and 6.8 mg of timolol maleate, equivalent to 5.0 mg of timolol.
Sodium chloride, benzalkonium chloride, sodium dihydrogen phosphate dihydrate, dodecahydrate of disodium hydrogen phosphate, purified water, sodium hydroxide for pH adjustment, hydrochloric acid for pH adjustment.
Appearance of the product and contents of the package
Latanoprost/Timolol Stada is aclear and colorless liquid, free of visible particles,packaged in a transparent dropper bottle with a screw cap.
Latanoprost/Timolol Stada is available in the following package sizes:
1 bottle containing 2.5 ml of eye drops in solution,
3 bottles each containing 2.5 ml of eye drops in solution,
6 bottles each containing 2.5 ml of eye drops in solution.
Only some package sizes may be commercially available.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder
STADA, S.L.
Frederic Mompou, 5
08960 Sant Just Desvern (Barcelona)
Spain
Responsible manufacturer
ROMPHARM COMPANY S.R.L.
Eroilor Street, no. 1A
Otopeni 075100, Ilfov district
Romania
or
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel
or
STADA Arzneimittel GmbH
Muthgasse 36
1190 Wien
Austria
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Denmark: | Latanostad Comp |
Austria: | Latanoprost/Timolol Stada 50 Mikrogramm/ml + 5 mg/ml Augentropfen |
Spain: | Latanoprost/Timolol Stada 50 microgramos/ml + 5 mg/ml eye drops in solution |
Finland: | Oftastad comp |
Portugal: | Latanoprost + Timolol Ciclum |
Romania: | Latanoprost/Timolol Stada HEMOFARM 50 micrograme/ml + 5 mg/ml, eye drops |
Republic | oftalmice, solution |
Slovakia: | LATIMOSTAD |
Last review of this leaflet was in:June 2022
Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.